The US Food and Drug Administration (FDA) has approved an oral form of azacitidine (Onureg) for use as maintenance therapy for patients with acute myeloid leukemia (AML) who have achieved a first complete remission.
The approval extends to patients who have achieved complete remission with incomplete blood count recovery following intensive induction chemotherapy and who are unable to complete intensive curative therapy.
The approval was based on data from the QUAZAR AML-001 trial, which showed that oral azacitadine significantly improved overall survival when compared to placebo.
"It's not too hard to get these patients into remission," Harry P. Erba, MD, PhD, director of the Leukemia Program at the Duke Cancer Institute, Durham, North Carolina, told Medscape Medical News last year, when these results were first presented at the 2019 annual meeting of the American Society of Hematology. "The problem comes in keeping them in remission."
Despite various attempts, there has been no success over the past 30 years in defining maintenance treatment for these patients, Andrew H. Wei, MBBS, PhD, from the Alfred Hospital in Melbourne, Australia, said.
"Oral azacitidine represents a new therapeutic standard for patients with AML in remission," he said.
Azacitidine is a hypomethylating agent that incorporates into DNA and RNA. It has long been used as an injectable therapy for the treatment of myelodysplastic syndromes.
The approval of the new oral formulation for the new indication of AML "is the culmination of over a decade of research and 13 preclinical and clinical trials," said Giovanni Caforio, M.D., chairman and chief executive officer of Bristol-Myers Squibb, in a statement.
The QUAZAR AML-001 trial was a phase 3, international study involving 472 patients with AML who were within achieving a first complete remission or remission with incomplete blood recovery. All patients has received intensive induction chemotherapy with or without consolidation treatment, per investigator preference prior to study entry, and were not candidates for hematopoietic stem cell transplant at the time of screening.
Patients were randomly assigned to receive either oral azacitidine 200 mg daily on days 1 to 14 of a repeat 28-day cycle (n = 278) or matching placebo (n = 274). Treatment was continued indefinitely until blast count was more than 15% or patients experienced unacceptable toxicity or underwent transplant.
At a median follow-up of over 41.2 months, the median overall survival was significantly longer for patients who received oral azacytidine, at 24.7 monthsvs 14.8 months for those who received placebo (P < .0009; hazard ratio [HR], 0.69).
Relapse-free survival was also significantly prolonged to 10.2 months for patients who received oral azacitidinevs 4.8 months for those who received placebo (HR, 0.65; P < .0001).
Serious adverse reactions occurred in 15% of patients who received azacytidine. Events that occurred in 2% of patients include pneumonia (8%) and febrile neutropenia (7%). There was one fatal event.
The most common adverse reactions were nausea (65%, 24%), vomiting (60%, 10%), diarrhea (50%, 21%), fatigue/asthenia (44%, 25%), constipation (39%, 24%), pneumonia (27%, 17%), abdominal pain (22%, 13%) arthralgia (14%, 10%), decreased appetite (13%, 6%), febrile neutropenia (12%, 8%), dizziness (11%, 9%) and pain in extremity (11%, 5%). Permanent discontinuation because of an adverse reaction occurred in 8% of patients.
For more from Medscape Oncology, join us on Twitter and Facebook.
See the original post:
FDA Approves First Maintenance Therapy for AML - Medscape
- Comprehensive Report on Animal Stem Cell Therapy Market 2021 | Size, Growth, Demand, Opportunities & Forecast To 2027 | ANIMAL CELL THERAPIES,... - December 22nd, 2020
- I Peace, Inc. and Avery Therapeutics announce collaboration to bring iPSC derived cell therapy for heart failure to the clinic - PRNewswire - December 22nd, 2020
- Creative Medical Technology Holdings Announces Successful Application of ImmCelz Immunotherapy for Treatment of Stroke - PRNewswire - December 22nd, 2020
- Glycostem and Ghent University sign license agreement on NK cell therapy technology - PRNewswire - December 22nd, 2020
- Stem Cell Therapy Market to See Massive Growth by 2026 Osiris Therapeutics, NuVasive - Farming Sector - December 22nd, 2020
- Medicine by Design symposium highlights importance of convergence in regenerative medicine and human health - News@UofT - December 22nd, 2020
- Global NK Cell Therapy and Stem Cell Therapy Market: Development, Current Analysis and Estimated Forecast to 2025 - The Courier - December 22nd, 2020
- ONK Therapeutics Announces Three Exclusive Option License Agreements, Which Extend and Strengthen its Dual-Targeted NK Cell Therapy Pipeline -... - December 22nd, 2020
- New Combination Therapy Tested By Children's May Offer Hope For Leukemia Patients - WVXU - December 22nd, 2020
- Ashley Cain says over 80,000 people registered for stem cell donation in 48 hours after appeal to save baby - The Sun - December 22nd, 2020
- Bayer and Atara Biotherapeutics Enter Strategic Collaboration for Mesothelin-Targeted CAR T-cell Therapies for Solid Tumors - Business Wire - December 7th, 2020
- New Cedars-Sinai Biomanufacturing Center to Spur Cell Therapies - Newswise - December 7th, 2020
- ALLO-715, Off-the-Shelf CAR T-Cell Therapy, Produces Early Promise in Multiple Myeloma - Cancer Network - December 7th, 2020
- Stem cell therapy in coronavirus disease 2019: current evidence and future potential - DocWire News - December 7th, 2020
- Magenta Therapeutics and bluebird bio Announce a Phase 2 Clinical Trial Collaboration to Evaluate Magenta's MGTA-145 for Mobilizing and Collecting... - December 7th, 2020
- Treatment to restore vision by injecting stem cells into the eye could help people with damaged eyesight - iNews - December 7th, 2020
- Bayer creates cell and gene therapy platform to support partners - FierceBiotech - December 7th, 2020
- Stem Cell Therapy Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19) - Cheshire Media - December 7th, 2020
- ASH Goes Remote as CAR T-Cell Therapy Competition Heats Up - AJMC.com Managed Markets Network - December 7th, 2020
- Hematologist Discusses the Impact a Myeloma CAR T-Cell Approval Would Have on the Treatment Landscape - DocWire News - December 7th, 2020
- Cilta-Cel CAR T-cell Therapy Impresses With High ORR in R/R Multiple Myeloma - Targeted Oncology - December 7th, 2020
- Are stable producer cells the future of viral vector manufacturing and when will allogeneic cell therapy take hold? - BioPharma-Reporter.com - December 7th, 2020
- Global Stem Cell Therapy Market Detailed Analysis Of Current Industry Figures With Forecasts Growth By 2027 - The Haitian-Caribbean News Network - December 7th, 2020
- Not All Patients With Relapsed DLBCL Referred for CAR T in Community Setting - Targeted Oncology - December 7th, 2020
- CRISPR and another genetic strategy fix cell defects in two common blood disorders - Science Magazine - December 7th, 2020
- Cell Therapy Market Size, Share, Market Research and Industry Forecast Report, 2020-2027 (Includes Business Impact of COVID-19) - Cheshire Media - December 7th, 2020
- UCLA receives $7.3 million grant to build state-of-the-art facility for developing gene, cell therapies - UCLA Newsroom - December 7th, 2020
- Celyad Oncology Provides Updates on Allogeneic and Autologous CAR T Programs at 62nd ASH Annual Meeting and Exposition - GlobeNewswire - December 7th, 2020
- Evolving Standards and Heated Debates in the Treatment of Newly Diagnosed Multiple Myeloma - Curetoday.com - December 7th, 2020
- New Drug Could Improve Effectiveness of Stem Cell Therapy - Pain News Network - December 4th, 2020
- Repairing the Brain With Stem Cells? A Conversation With Prof. Jack Price - Being Patient - December 4th, 2020
- Hematologist/Stem Cell Biologist to Direct Hematology and Cellular Therapy at Cedars-Sinai - Newswise - December 4th, 2020
- CRISPR tagging used to grow neuronal cells from stem cells - Drug Target Review - December 4th, 2020
- How Stem Cell Therapy Market Will Dominate In Coming Years? Report Covering Products, Financial Information, Developments, Swot Analysis And... - December 4th, 2020
- Stem Cell Therapy Market to Witness Robust Expansion Throughout the Forecast Period 2020 2025 - The Haitian-Caribbean News Network - December 4th, 2020
- Stem Cell Therapy Market Expansion Projected to Gain an Uptick During 2020-2027 - The Haitian-Caribbean News Network - December 4th, 2020
- IN8bio announces first-in-human Phase 1 trial Update from The University of Kansas Cancer Center using INB-100, IN8bios Gamma Delta T-cell product... - December 4th, 2020
- Cancer Stem Cell Therapy Market Segmentation By Qualitative And Quantitative Research Incorporating Impact Of Economic And Non-Economic Aspects By... - December 4th, 2020
- CAR T-Cell Therapy Shows Promising Early Results in Children With Neuroblastoma - Technology Networks - December 4th, 2020
- Global Animal Stem Cell Therapy Market Research Report by Size, Data, Developments, Global Demand, In-Depth Analysis and Forecast 2020 to 2025 |... - November 27th, 2020
- Stem Cell Therapy Market Size, Growth, Demand, Opportunities & Forecast To 2025 - Cheshire Media - November 27th, 2020
- Celularity Announces Dosing of First Patient in Phase I Study of Human Placental Hematopoietic Stem Cell-Derived Natural Killer Cells (CYNK-001) in... - November 27th, 2020
- Scientists Reveal a New Drug That Directs Stem Cells To Desired Sites - Science Times - November 27th, 2020
- Global Stem Cells Market is estimated to account for US$ 18289.9 Mn by end of 2027, Says Coherent Market Insights (CMI) - Business Wire - November 27th, 2020
- Stem Cell Therapy Market To Observe Exponential Growth By 2020-2027 | Reports Globe - Cheshire Media - November 27th, 2020
- Ash 2020 cell therapy preview the battle for recognition - Vantage - November 27th, 2020
- Animal Stem Cell Therapy Market 2020 to Flourish with an Impressive CAGR of XX% in the year 2026, Market Size & Growth with Complete Business... - November 27th, 2020
- Adipose Tissue-derived Stem Cell Therapy Market: Worldwide Industry to Boost in the Period of 2020-2025 - Express Journal - October 19th, 2020
- Global Stem Cell Therapy Market 2020: Trends, and Opportunity Analysis, Top Manufacturers And Forecast to 2027 - PRnews Leader - October 19th, 2020
- Stem Cell Therapy Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19) - Eurowire - October 19th, 2020
- Global Adipose Tissue-derived Stem Cell Therapy Market 2020 Demand, Business Growing Strategies, Industry Segmentation and Forecast 2025 -... - October 19th, 2020
- Stem Cell Therapy Market Trends, Opportunities, New Technologies and Developments, Competitor analysis and Market Sizing from 2020 to 2026 - PRnews... - October 19th, 2020
- Global Adipose Derived Stem Cell Therapy Market 2020 Demand, Business Growing Strategies, Industry Segmentation and Forecast 2025 - TechnoWeekly - October 19th, 2020
- Notch Therapeutics Strengthens Leadership Team with Appointment of Kamran Alam as CFO and Gregory Block as SVP, Corporate Development - PRNewswire - October 19th, 2020
- Stem Cell Therapy Market To Observe Exponential Growth By 2020-2027 | Verified Market Research - Stock Market Vista - October 19th, 2020
- Stem Cell Therapy Market 2020 growth factors, latest trend and regional analysis of leading players by 2025 - News by Decresearch - October 19th, 2020
- Cell Therapy Market Size, Share, Market Research and Industry Forecast Report, 2020-2027 (Includes Business Impact of COVID-19) - Eurowire - October 19th, 2020
- Autologous Cell Therapy Market is Anticipated to Expand at a CAGR of 18.1% from 2019 to 2027 - Eurowire - October 19th, 2020
- Cell Therapy Market Trend,COVID-19 Impact,Current Industry Figures With Demand By Countries And Future Growth - PRnews Leader - October 19th, 2020
- Gamida Cell and Be The Match BioTherapies Expand Strategic Collaboration - BioSpace - October 19th, 2020
- Cell Therapy Manufacturing Market to be Worth USD 8 billion by 2030, predicts Roots Analysis - The Think Curiouser - October 19th, 2020
- Novellus Therapeutics Exclusively Licenses Induced Mesenchymal Stem Cells (iMSCs) to NoveCite for COVID-19 Related Acute Respiratory Distress Syndrome... - October 19th, 2020
- UofL-born company secures an additional $115 million to advance cell therapy - uoflnews.com - October 19th, 2020
- Global and United States Cancer Stem Cell Therapy Market Leading Players Expected to Witness the Highest Growth 2025 | AVIVA BioSciences, AdnaGen,... - October 19th, 2020
- Can Stem Cell Therapy Repair Damaged Knees? - September 2nd, 2020
- Vor Biopharma and Metagenomi to Collaborate on Engineered Hematopoietic Stem-Cell Therapies - Business Wire - September 2nd, 2020
- COVID-19 cell therapy drives Mesoblast to seek manufacturing muscle - BioPharma-Reporter.com - September 2nd, 2020
- New Report Begins a New Era of Stem Cell Science and Medicine: Stem Cell Biotechnology Company Asymmetrex Tells How It Counts Therapeutic Tissue Stem... - September 2nd, 2020
- Optimized Freezing Solutions for Clinical Application of Cell Therapy Products - Technology Networks - September 2nd, 2020
- Global Cord Blood Banking Market 2020 with Analysis of 44 Industry Players - PRNewswire - September 2nd, 2020
- Cartesian Therapeutics Initiates Clinical Trial of First RNA-Engineered Cell Therapy for Acute Respiratory Distress Syndrome and COVID-19 - PRNewswire - September 2nd, 2020
- New Comprehensive Report on Stem Cell Therapy Market to Witness an Outstanding Growth during 2020 2025 with Top Players Like Chiesi Pharmaceuticals,... - September 2nd, 2020
- CAR T-Cell Optimization Starts in Production, Extends to Therapy - Genetic Engineering & Biotechnology News - September 2nd, 2020
- Ruxolitinib May Be Another Option for Children With Steroid Refractory aGVHD - AJMC.com Managed Markets Network - September 2nd, 2020
- Growing Focus on R&D Likely to Accelerate the Growth of the Stem Cell Therapy Market - The News Brok - September 2nd, 2020
- Oldest male polar bear on record humanely euthanized at Point Defiance Zoo - MyNorthwest.com - September 2nd, 2020
- Elixirgen Therapeutics planning to begin Phase I/II Clinical Trials of its COVID-19 Vaccine Candidate EXG-5003 at Fujita Health University -... - September 2nd, 2020
- Hill Highlights the Potential of Selinexor as a Less Intensive Option for DLBCL - OncLive - September 2nd, 2020
- Global Rheumatoid Arthritis Stem Cell Therapy Market Dynamics, Forecast, Analysis and Supply Demand 2018 to 2028 - Scientect - September 2nd, 2020
- Growing at an annualized rate of over 20%, the cell therapy manufacturing market is estimated to reach close to USD 10 Billion by 2030, claims Roots... - September 2nd, 2020